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ABSTRACT
Objective: To evaluate oncological outcomes of Kidney Sparing Surgery (KSS) for upper 
urinary tract transitional cell carcinoma (UUT-TCC).
Patients and Methods: We performed a retrospective review of patients who underwent 
segmental ureterectomy or endoscopic treatment (percutaneous nephroscopy or retrograde 
ureteroscopy) for UUT-TCC between 1991 and 2006 at our institution. We evaluated 
recurrence-free and overall survival rates following KSS. There were 40 renal units in 
38 patients. Three patients had bilateral synchronous disease. Mean patient age (±SD) 
was 69.8±12.3 years. Eighteen (47%) patients had a prior history of bladder TCC. Sixteen 
(40%) segmental ureterectomies and 24 (60%) endoscopic treatments were performed. Six 
(16%) patients received adjuvant BCG. Grade distribution was 24 (60%) low-grade, 12 
(30%) high-grade and 4 (10%) Gx. The mean follow-up was 47 months.
Results: Recurrence rate was 32.5%. The three and five-year recurrence-free survivals were 
59.5% and 42.4%. Tumor location was predictive for recurrence (p <0.03). The three and five-
year overall survivals were 91.6% and 79.8%. Predictive variables for overall survival were 
tumor grade (p <0.008) and stage (p <0.018) and previous history of bladder TCC. There was a 
statistically significant correlation (r= 0.3539) between tumor grade and stage (p= 0.027).
Conclusions: KSS offers good oncological outcomes in selected patients with UUT-TCC. 
The tumor biology rather than the surgical approach dictates prognosis. Patients with higher 
stage and grade disease may be better served with a more aggressive treatment approach.
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INTRODUCTION                                    
Upper urinary tract transitional cell carcinoma 
(UUT-TCC) is less common than bladder 
cancer, accounting for approximately 5% of 
urothelial malignancies and less than 10% of 
renal tumors1. Radical nephroureterectomy 
(RNU) with excision of the ipsilateral ureteral 
orifice and bladder cuff has been considered 
the standard of care of UUT-TCC due to 
the high recurrence rate and multiplicity in 
the same renal unit and the low incidence 
of bilateral disease2. However, in patients 
with impaired renal function, solitary kidney, 
bilateral synchronous tumors and high surgical 
risk, Kidney Sparing Surgery (KSS) may 
be a preferred option. Developing literature 
suggests that select patients with normal 
contralateral kidney and solitary, small, low 
grade and stage tumors may also be considered 
for organ sparing approaches3. KSS of UUT-
TCC encompasses a spectrum of ablative 
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and endoscopic approaches aimed at organ 
preservation. KSS can be achieved by partial 
ureterectomy or endoscopic surgery.
Multiple studies have confirmed the efficacy 
and safety of endoscopic treatment of UUT-
TCC. Tawfiek and Bagley reported on the 
outcome of ureteroscopic management 
for UUT-TCC from 14 series and found a 
recurrence rate of 33% for 61 renal pelvic 
tumors and 31% for 144 ureteral tumors4. 
Tumor recurrence was most dependent upon 
tumor grade with 25% recurrence for grade 
I tumors and almost 50% for higher grade 
lesions5. Percutaneous antegrade approach, 
although more invasive, is preferred for more 
substantial tumors in the renal pelvis and 
proximal ureter. It provides better visualization 
and large caliber working instruments for 
larger size tumors. In a literature review of 84 
patients, an overall recurrence rate of 27% was 
found, with tumor grade strongly predicting 
outcomes6. Recently, Roupret and colleagues 
noted a similar 30% recurrence rate with 
5-year disease specific survival of 80%7.
Segmental ureterectomy is a widely accepted 
form of KSS. It can be applied for invasive 
tumors and has the added advantage of 
staging lymphadenectomy. However, it is 
mainly limited to distal ureteral tumors and 
occasional mid or proximal ureteral defects 
that can be primarily approximated.
The aim of this study was to assess the 
oncological outcomes of patients with 
primary UUT-TCC treated with KSS. KSS.
PATIENTS AND METHODS                   
We performed a retrospective chart 
review of patients who underwent segmental 
ureterectomy and endoscopic treatment 
(percutaneous nephroscopy or ureteroscopy) 
for UUT-TCC between January 1991 and 
December 2006 at Mc Gill University Health 
Center. The recorded data included patient 
demographics, tumor characteristics (stage, 
grade, site and focality), prior history of 
bladder cancer, type of treatment, indication 
for surgery and adjuvant BCG instillation. 
We evaluated recurrence-free and overall 
survival rates following KSS.
There were 38 patients with 40 renal units. 
The male to female ratio was 3:1. The median 
age of patients was 72 years (32-88 yrs). 
Eighteen (47%) patients had a prior history of 
bladder TCC. The primary tumor was located 
in the kidney, ureter or both in 11 (27.5%), 28 
(70%) and 1 (2.5%) of renal units, respectively. 
Three (8%) patients had bilateral UUT-TCC 
at the time of diagnosis. Unifocal disease was 
found in 29 (72.5%) and multifocal disease in 
11 (27.5%) renal units.
Pathologic grade was available for 36 
tumors and pathologic stage was available for 
32 tumors. Tumor grade was not available in 
four patients because of insufficient tissue for 
pathological examination (3 patients treated 
with laser fulguration and one treated with 
double-J stenting and BCG instillation). Twenty 
four (60%) tumors were low grade, 12 (30%) 
high grade and the remainder unknown (Gx). 
Twenty three (57.5%) tumors were superficial 
(CIS, Ta, T1), 7 (17.5%) invasive (T2, T3) and 
8 (20%) had undetermined stage (Tx). 
Follow-up of the UUT was conducted with 
intravenous pyelography (IVP) or retrograde 
pyelography with selective urine cytology at 
6-month intervals. Computed tomography (CT) 
scan and other imaging studies were performed 
as indicated clinically. Diagnostic ureteroscopy 
was performed if imaging studies were 
suspicious for recurrence or if urine cytology 
was positive. Follow-up of the lower urinary 
tract was performed with cystourethroscopy 
and urine cytology every 3 months.
Univariate analysis using the log-rank test 
was performed to assess the predictive value 
of potential prognostic factors. Kaplan-Meier 
curves were generated for recurrence-free 
and overall survival. Stage versus grade 
correlation was done using Spearman’s rank 
correlation test. Missing data were censored. 
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RESULTS                                                        
Indications and treatment approaches are 
summarized in (Table 2). There were 26 
(65%) electively treated tumors and 14 (35%) 
imperative indications such as solitary kidney, 
high surgical risk and bilateral disease. Twenty 
four (60%) tumors underwent endoscopic 
treatment and 16 (40%) had segmental 
ureterectomy. Of ureteral tumors treated 
endoscopically, sixteen were fulgurated with 
Holmium laser and 2 were resected.
Six (15%) renal units received adjuvant 
6-weekly BCG after initial endoscopic 
treatment. The indication for BCG instillations 
was high-grade tumors in two cases and 
incomplete resection in five cases. Four units 
received intravesical BCG instillations with 
double pigtail catheter insertion and two units 
received percutaneous BCG instillations 
via nephrostomy tube. None of the patients 
received adjuvant systemic chemotherapy. 
Recurrence=free survival was calculated 
from the day of initial treatment to the day 
of diagnosis of the first recurrence in the same 
renal unit. Disease recurrence occurred in 13 
(32.5%) renal units. The mean and median 
times to recurrence were 31.8 and 17 months, 
respectively (range 1 to 139 months). The 
three and 5-year recurrence-free survivals 
were 59.5% and 42.4%, respectively. Nine 
recurrences were located at the same site as 
the initial tumor, two recurred at a lower level 
and two recurred at a higher level.  Recurrence 
was multifocal in three patients. Treatment 
at recurrence was endoscopic management 
in five units, nephroureterectomy in 4 units, 
segmental ureterectomy in one patient and 
palliative therapy in one patient. Two patients 
were treated at an outside institution at the 
time of recurrence. Fifteen (40%) patients 
had bladder TCC recurrence, 5 (13%) of 





Median age (yrs) (range) 71 (32-88)






Upper Ureter 6 (15%)
Lower Ureter 20 (50%)
Upper and Lower Ureter 2 (5%)




Synchronous bilateral UUT-TCC 3 (8%)
Table 1: Clinical characteristics of 38 patients 




Solitary Kidney 5 (12.5%)
Surgical Risk 5 (12.5%)
Bilateral Disease 4 (10%)
Treatment 
Partial Ureterectomy 16 (40%)
Endoscopic management 24 (60%)
Ureteroscopy 18 (45%)
Percutaneous 5 (12.5%)
JJ and BCG instillation 1 (2.5%)
Table 2: Indication and treatment of UUT-TCC 
in 40 renal units
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Univariate analysis of studied prognostic 
factors for recurrence-free survival is shown 
in Table 3. Tumor location was a significant 
predictive factor for recurrence (p <0.03). 
Age, sex, indication for surgery, tumor 
stage, grade, focality, surgical procedure 
and adjuvant BCG were not statistically 
significant. Tumor location within the kidney 
(renal pelvis or calyx) portended a higher risk 
of recurrence compared to ureteral location 
(HR 4; 95% CI 1.19-13.53). The recurrence 
rates were 50% and 25% for kidney and 
ureteral locations. Five-year recurrence-free 
survival for kidney and ureteral locations 
was 29% and 49%, respectively (p <0.03).
Tumor grade did not reach significance, but 
the recurrence rates for high versus low grade 
tumors were 50% and 29%, respectively.
Overall survival time was calculated from 
the day of treatment to the last known 
follow-up or death date. There were 4 deaths, 
3 from metastatic TCC and one from cardiac 
arrest during bypass surgery. The disease-
specific survival rate was 92.1%. The three 
and 5-year overall survivals were 91.6% 
and 79.8% (Fig. 1). Median survival was not 
yet reached. Mean and median follow-up 
times were 47 and 32 months, respectively 
(range 1-219 months).
Univariate analysis of studied prognostic 
factors for survival is shown in (Table 3). 
There was a significant difference in overall 
survival when stratified by tumor stage 
(p <0.018), grade (p <0.008) and history of 
bladder TCC before detection of UUT-TCC 
(p <0.002). Age, sex, indication for surgery, 
tumor focality and location, surgical approach 
and adjuvant BCG were not significant. Fig.1 
shows Kaplan-Meier curves of significant 
variables. Survival rates were 100% and 79% 
for superficial (Ta, T1) and invasive (T2, T3) 
tumors, respectively. Five-year estimated 
overall survival was 100% for superficial 
(Ta, T1) and 53.6% for invasive (T2, T3) 
tumors. The survival rates for low and high-
grade tumors were 100% and 75%.
There were 4 complications as a result of 
KSS. One patient had stenosis of the ureteric 
orifice after ureteroscopic resection of 
Recurrence Overall Survival
Variable Hazard Ratio 




(95% CI of ratio)
p value
(95% )
Age (>70 vs. ≤70 years) 1.98 (0.71-5.55) 0.2 2.6 (0.36-18.53) 0.34
Sex (Male vs. Female) 0.76 (0.22-2.62) 0.66 3.59 (0.33-38.74) 0.29
Bladder TCC (Prior BT vs No Prior BT) 2.33 (0.78-6.92) 0.13 29.38 (3.35-257.9) 0.002*
Indications (Imperative n=14 vs. Elective n=26) 1.52 (0.47-4.88) 0.48 3.91 (0.4-38.04) 0.24
Stage (Invasive, n=7 vs. Superficial, n=23) 0.67 (2-2.26) 0.52 17.26 (1.6-186.3) 0.018*
Grade (High, n=12 vs. Low, n=24) 2.21 (0.71-6.86) 0.17 27.85 (2.33-333.4) 0.008*
Focality (Multifocal, n=12 vs. Unifocal, n=28) 0.72 (0.23-2.27) 0.58 3.25 (0.35-29.72) 0.29
Location (Kidney, n=12 vs. Ureter, n=28) 4 (1.19-13.53) 0.03* 0.27 (0.03-2.74) 0.27
BCG (no BCG, n=33 vs. BCG, n=7) 3.4 (0.74-15.6) 0.12 2.18 (0.14-34.54) 0.58
Surgical Procedure
(Endoscopic, n=24 vs. Partial Ureterectomy, n=15) 1.28 (0.46-3.58) 0.64 0.321 (0.05-2.3) 0.26
Table 3: Univariate analysis of potential prognostic factors for recurrence and overall survival
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ureteral TCC that was treated by endoscopic 
dilatation. One patient had a stricture of the 
ureteropelvic junction in a single kidney 
after percutaneous resection of renal pelvic 
tumor, which resulted in renal failure and 
hemodialysis. Systemic tuberculosis occurred 
after the third installation of BCG following 
percutaneous resection of renal pelvic TCC in 
one patient. BCG installations were stopped 
and the patient received medical treatment 
for TB. Another patient with a single kidney 
lost its function after percutaneous resection 
and BCG installation and was referred for 
hemodialysis.
Among the 40 renal units initially treated by 
KSS, four kidneys were removed due to tumor 
recurrence. Three units were treated initially 
with partial ureterectomy and one was treated 
endoscopically. Two nonfunctioning kidneys 
were left in place. The final kidney sparing 
rate was 85%.
There was a statistically significant correlation 
(r= 0.354) between tumor grade and stage 
(p= 0.027).
DISCUSSION                                                   
Multiple therapeutic options are available 
for the management of UUT-TCC. RNU 
with bladder cuff is considered the gold 
standard treatment. According to the National 
Fig. 1: (A) Overall survival. (B) Stratification of survival by tumor stage (p <0.018). (C) Stratification of survival by prior history of 
bladder TCC (p <0.002). (D) Stratification of survival by tumor grade (p <0.008).
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Comprehensive Cancer Network guidelines, 
KSS is the preferred option for low grade, 
mid and distal ureteral TCC and second line 
option for low grade, renal pelvic and upper 
ureteral TCC8. The European Association of 
Urology guidelines on TCC do not provide 
clear recommendations about KSS9. To our 
knowledge, there are no published guidelines 
on UUT-TCC from the American Urological 
Association or the Canadian Urological 
Association.
Several reports advocate the use of KSS 
for UUT-TCC in patients with solitary 
kidney, bilateral tumors, renal insufficiency 
and in patients with high risk for major 
surgery. The latter are considered imperative 
indications for KSS. However elective KSS 
is being performed successfully in patients 
with small, low grade and low stage 
tumors3, 4. Elective KSS in selected patients 
is justified by the fact that prognostic 
factors for recurrence and survival are 
tumor related irrespective of the treatment 
modality4. Several case series suggested 
that outcomes of KSS in appropriately 
selected patients were no different than the 
gold standard RNU4, 10.
In our study, we report the oncological 
outcomes of 38 patients who underwent 
KSS for 40 renal units. We acknowledge 
the limitations of this retrospective non-
randomized single center cohort study. 
However, the strengths of the study include 
a fair number of patients and systematic 
and comprehensive analysis of potential 
predictors of both recurrence and survival. 
Clinical characteristic are similar to those 
reported by others2, 10, 11. Prior history of 
bladder TCC was found in 18 (47%) patients. 
This figure is higher than reported by previous 
series (16%-19%)2, 11. Fifteen (40%) patients 
developed bladder recurrence after KSS, 
only 5 (13%) of which were de novo bladder 
recurrences. Fujimoto et al12, reported a 
similar incidence of bladder recurrence after 
UUT-TCC treatment. In other series bladder 
TCC recurrences were as low as 16.7% 
and as high as 51%2, 7. We think that those 
patients could be served better with routine 
endoscopic surveillance, however, there were 
no guidelines for follow-up of such patients 
in our institution.
In this series, the 3- and 5-year recurrence-
free survivals were 59.5% and 42.4%, 
respectively. Ipsilateral recurrence of the 
disease was 32.5%. This recurrence rate is 
similar to that reported in previous series13. 
The risk of ipsilateral recurrence after KSS 
ranges from 7% to 70%2, 7, 10-12, 14. In the 
current study the recurrence rate for low 
grade disease was 29% and for high grade 
disease was 50% (p NS). Zincke and Neves14 
reported only 5% recurrence for grade 1-2 
ureteral TCC and 50% recurrence for higher 
grades. However, Keely et al, reported 26% 
recurrence rate for grade 1-2 and 44% in 
higher grades5.
In this series, we established tumor location 
as a predictor of recurrence following 
KSS. Five-year recurrence-free survival 
for pelvicalyceal system and ureteral TCC 
was 29% and 49% respectively (p <0.03). 
Similarly, Iborra et al reported tumor location 
in the renal pelvis as a significant predictive 
factor for tumor recurrence13. 
Five-year overall survival after KSS was 
reported in a range from 56% to 91.7%7,11, 12, 15. 
In the current study the 3- and 5-year overall 
survivals were 91.6% and 79.8%. Prognostic 
predictors for overall survival were tumor 
stage, tumor grade and bladder TCC prior 
to detection of UUT-TCC (Table 3). Five-
year overall survival was 100% in pTa and 
pT1 and 53.6% in pT2 and pT3 stages. These 
results are comparable to those reported by 
Zungri et al., 100% in pTa , 95.8% in pT1 and 
33.3% in pT215. We found a 100% survival 
rate in low grade disease and 75% in high 
grade disease, which is in accordance with 
other reports11, 14. 
There was a strong correlation between 
grade and stage of UUT-TCC (p <0.027). 
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Most low grade tumors were non-invasive, 
which is in agreement with published data2,16. 
CONCLUSION                                       
KSS offers good oncological outcomes in 
selected patients with UUT-TCC. The tumor 
biology rather than the surgical approach 
dictates prognosis. Renal location portends a 
higher risk of recurrence compared to ureteral 
location. Long term, thorough surveillance 
is required, since recurrence of the disease 
may occur as late as five years. Prior history 
of bladder cancer negatively affects survival 
in a highly significant manner. Patients with 
higher stage and grade disease may be better 
served with a more aggressive treatment 
approach.
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